| Bioactivity | PPARα/γ agonist 4 (Compound (S)-7) is an orally active dual potent agonist of PPARα and PPARγ, with EC50 values of 0.061 μM and 1.42 μM respectively. PPARα/γ agonist 4 acts through an insulin-independent mechanism and exhibits mitochondrial pyruvate carrier inhibition and anti-diabetic properties. PPARα/γ agonist 4 is expected to be used in research for dyslipidemic type 2 diabetes[1]. |
| Invitro | PPARα/γ agonist 4 (100 nM, 24 小时) 能够增加 C2C12 细胞系的葡萄糖的摄取和代谢，并通过增强脂肪酸降解的线粒体活性避免肝细胞或肌肉细胞中的脂质积累[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> PPARα/γ agonist 4 相关抗体: |
| In Vivo | PPARα/γ agonist 4 (25 mg/kg, 50 mg/kg, 口服, 治疗15天) 在糖尿病小鼠模型中以剂量依赖方式发挥抗高血糖作用，同时具有显著降脂功效[1]。药代动力学分析[1] PPARα/γ agonist 4 |
| Formula | C25H20O3 |
| Molar Mass | 368.42 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Laghezza A. A chemical modification of a peroxisome proliferator-activated receptor pan agonist produced a shift to a new dual alpha/gamma partial agonist endowed with mitochondrial pyruvate carrier inhibition and antidiabetic properties. Eur J Med Chem. 2024; 275:116567. |